The Push for American-Made Peptides
A movement to bring peptide production back to the US gains momentum.
1Peptide Party on a WWII Ship
A black-tie event aboard the SS Jeremiah O’Brien, a WWII Liberty ship, hosted by Gen Z venture capitalists from Haus Fund, highlighted the push for American-made peptides. Attendees sampled peptide products, including GHK-Cu cream and sublingual strips from startup Afterglow. The venue symbolized American industrial strength and the need to relocate pharmaceutical production to the US.
2Gray Market Concerns
The US Department of Health and Human Services recently allowed unapproved peptides for compounding, aiming to address gray-market issues. Critics argue this bypasses clinical trials, creating a parallel, less-regulated market. FDA scientists have expressed concerns about the safety and efficacy of these peptides, citing insufficient evidence.
3Venture Capitalists’ Vision
Roxana Grunenwald, Yuva Krishnapillai, and Elia Ahmadi of Haus Fund advocate for American peptide production. They argue that domestic manufacturing ensures regulatory oversight and consumer safety. Their event emphasized the slogan 'My Peptides Are Made in America,' reflecting their commitment to onshoring production.
4Global Pharmaceutical Dependence
Over half of US prescription active pharmaceutical ingredients come from India and the EU, with China contributing 10%. Gray-market peptides, often labeled 'Chinese peptides,' dominate online sales. This reliance on foreign suppliers raises concerns about quality control and consumer recourse in case of issues.
5Regulatory Challenges
The HHS’s interim decision allows compounding pharmacies to create a US-based peptide supply chain. This could provide the FDA with better market oversight and pave the way for new API classifications. However, building this infrastructure is costly and time-consuming, with no guarantee of long-term policy support.
6Hims & Hers’ Initiative
Hims & Hers, a prominent telehealth brand, is investing in US peptide production. They recently acquired a California facility and plan to launch Peptides Plus, offering compounds like Sermorelin and Glutathione. CEO Andrew Dudum emphasizes the importance of domestic oversight for quality and safety.
7Cost and Accessibility
American-made peptides are expected to be more expensive due to higher production costs. While some consumers prioritize quality and safety, affordability remains a key factor driving demand for cheaper, gray-market alternatives. Balancing cost and regulatory compliance will be a significant challenge.
8Broader Implications
The push for American peptides reflects broader trends in reshoring critical industries, similar to efforts in semiconductors and electronics. Advocates argue that domestic production ensures regulatory consistency and consumer accountability, setting global standards for safety and quality in the peptide market.
9Uncertain Future
The HHS’s interim policy is not a permanent solution, and its impact on the peptide economy remains unclear. Midterm elections and tariff policies could influence its trajectory. While the movement for American-made peptides gains traction, its long-term success depends on sustained investment and regulatory support.
Original article: The Verge (theverge.com) — The Push for American-Made Peptides